iBio

iBio is a preclinical biotechnology company using artificial intelligence, computational biology, and antibody-engineering technologies to develop precision therapeutics for obesity, cardiometabolic disease, cancer, and other difficult-to-treat conditions. The company also pursues licensing and collaboration opportunities involving its antibody discovery platform and preclinical assets.

Relationship details are part of the Pro plan.